Azenta Inc

Life sciences company Azenta announced on Friday that it has completed the divestiture of its B Medical Systems after Thelema S.à r.l., which acquired the medical refrigeration devices maker in July, repaid a $35 million vendor loan related to the deal. The Luxembourg-based Thelema completed the purchase of B Medical Systems following a 2025 deal worth $63 million, with $35 million of that funded through a short-term vendor loan from an Azenta subsidiary. The vendor loan was repaid in full ahead of maturity along with accrued interest, and Azenta has released the equity interests tied to the deal, completing the divestiture. Interim CEO Martin Madaus said Azenta has now received the entire purchase price in cash, and the credit exposure associated with the transaction has been retired, supporting the company's disciplined approach to capital allocation.

Repligen reported second-quarter revenues of $204.1 million, up 11.9% year over year and exceeding analysts' expectations by 1.1%. The company also beat analysts' EPS and organic revenue estimates, with President and CEO Olivier Loeillot citing 13% organic growth and increased full-year guidance. Among the eight drug development inputs and services stocks tracked, the group's revenues beat consensus estimates by 4.1% on average, while next quarter's revenue guidance came in 0.8% above expectations. Repligen delivered the weakest performance against analyst estimates and the weakest full-year guidance update of the group, yet its stock is up 29.4% since reporting and currently trades at $169.56. Azenta posted the best Q2 with revenues of $161.2 million, up 12% year over year and beating estimates by 8%, while IQVIA reported revenues of $4.37 billion, up 8.7% year over year and exceeding expectations by 1.5%.

Azenta Inc reported total revenue of $161 million for the third quarter of fiscal 2026, up 12% as reported and 9% organically year-over-year, driven by strong performance in biorepositories and its C&I business. Sample Management Solutions revenue reached $88 million, up 14% reported and 9% organically, while Multiomics revenue was $73 million, up 10% reported and 8% organically. Gross margin declined 140 basis points to 46.2%, with Sample Management gross margin down 750 basis points to 45.9% due to lower volumes and quality remediation costs, partially offset by a 550-basis-point improvement in Multiomics gross margin to 46.5%. Adjusted EBITDA margin was approximately 11.4%, down 60 basis points year-over-year but up 610 basis points sequentially, and non-GAAP EPS came in at $0.16. The company repurchased approximately 2.3 million shares for $50 million and ended the quarter with $529 million in cash and marketable securities. For the full year, Azenta expects revenue in the range of $613 million to $618 million, with organic revenue approximately flat to up 1%, and adjusted EBITDA between $59 million and $62 million.

Zacks Investment Research added five stocks to its Zacks Rank Number 1 Strong Buy list on July 16. B2Gold Corp saw its current-year earnings consensus estimate rise 7.7 percent over the last 60 days. Apogee Enterprises and Azenta each recorded a 7.1 percent increase in their current-year earnings consensus estimates over the same period. Afya's current-year earnings consensus estimate climbed 6.5 percent, while Kinross Gold's rose 6.1 percent.

Azenta has completed the sale of its B Medical Systems business to Thelema for a fixed purchase price of $63 million. The deal, which closed on July 1, 2026, was previously announced on December 29, 2025. B Medical Systems, a provider of cold chain medical solutions, was originally acquired by Azenta in 2022. To facilitate the transaction, Azenta Germany GmbH extended a $35 million vendor loan to Thelema, carrying 6% annual interest and maturing in three months. The company stated the divestiture will simplify its portfolio and sharpen focus on core life sciences operations.